X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Strides Arcolab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs STRIDES SHASUN LTD - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA STRIDES SHASUN LTD GLENMARK PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x 20.0 34.4 58.0% View Chart
P/BV x 3.6 0.9 388.6% View Chart
Dividend Yield % 0.3 1.1 31.4%  

Financials

 GLENMARK PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
STRIDES SHASUN LTD
Mar-17
GLENMARK PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs9931,275 77.9%   
Low Rs729918 79.4%   
Sales per share (Unadj.) Rs325.5389.6 83.6%  
Earnings per share (Unadj.) Rs39.328.0 140.5%  
Cash flow per share (Unadj.) Rs48.748.9 99.5%  
Dividends per share (Unadj.) Rs2.004.50 44.4%  
Dividend yield (eoy) %0.20.4 56.6%  
Book value per share (Unadj.) Rs159.2303.1 52.5%  
Shares outstanding (eoy) m282.1789.42 315.6%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.62.8 94.0%   
Avg P/E ratio x21.939.2 55.9%  
P/CF ratio (eoy) x17.722.4 78.9%  
Price / Book Value ratio x5.43.6 149.5%  
Dividend payout %5.116.1 31.6%   
Avg Mkt Cap Rs m242,99198,036 247.9%   
No. of employees `00013.05.8 223.6%   
Total wages/salary Rs m16,4085,881 279.0%   
Avg. sales/employee Rs Th7,083.96,005.9 117.9%   
Avg. wages/employee Rs Th1,265.41,014.0 124.8%   
Avg. net profit/employee Rs Th855.1431.2 198.3%   
INCOME DATA
Net Sales Rs m91,85734,834 263.7%  
Other income Rs m3741,686 22.2%   
Total revenues Rs m92,23036,520 252.5%   
Gross profit Rs m20,3676,428 316.8%  
Depreciation Rs m2,6441,872 141.3%   
Interest Rs m2,3732,269 104.6%   
Profit before tax Rs m15,7243,973 395.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m-810-1,006 80.5%   
Tax Rs m3,827470 814.2%   
Profit after tax Rs m11,0882,501 443.3%  
Gross profit margin %22.218.5 120.2%  
Effective tax rate %24.311.8 205.7%   
Net profit margin %12.17.2 168.1%  
BALANCE SHEET DATA
Current assets Rs m68,74638,165 180.1%   
Current liabilities Rs m27,02730,402 88.9%   
Net working cap to sales %45.422.3 203.8%  
Current ratio x2.51.3 202.6%  
Inventory Days Days8577 109.9%  
Debtors Days Days96104 91.4%  
Net fixed assets Rs m24,13237,639 64.1%   
Share capital Rs m282894 31.6%   
"Free" reserves Rs m44,64326,210 170.3%   
Net worth Rs m44,92527,105 165.7%   
Long term debt Rs m45,36316,377 277.0%   
Total assets Rs m117,63981,168 144.9%  
Interest coverage x7.62.8 277.2%   
Debt to equity ratio x1.00.6 167.1%  
Sales to assets ratio x0.80.4 181.9%   
Return on assets %11.45.9 194.7%  
Return on equity %24.79.2 267.5%  
Return on capital %19.112.1 158.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15213,465 417.0%   
Fx outflow Rs m8,0844,076 198.3%   
Net fx Rs m48,0689,389 511.9%   
CASH FLOW
From Operations Rs m6,5742,881 228.2%  
From Investments Rs m-7,124-7,051 101.0%  
From Financial Activity Rs m5,4323,382 160.6%  
Net Cashflow Rs m1,992-788 -253.0%  

Share Holding

Indian Promoters % 48.3 27.7 174.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 37.8 18.3%  
FIIs % 34.4 8.6 400.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 25.9 40.5%  
Shareholders   56,727 56,241 100.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFE  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; Pharma & Realty Stocks Gain(09:30 am)

Asian share markets are mixed today. The Nikkei 225 is flat while the Hang Seng is down 0.1%. The Shanghai Composite is trading down by 1.1%.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 20, 2018 09:31 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS